Block and bulk deals involve large transactions executed on stock exchanges. A block deal is defined as a single trade involving at least 5 lakh shares, or a total transaction value of Rs. 10 crore or more. In contrast, a bulk deal is characterised by transactions involving more than 0.5 percent of a company’s total equity shares.
Following are two penny stocks that witnessed positive price fluctuations despite the selling activities of foreign portfolio investors:
Leading Leasing Finance & Investment Company Limited
With a market cap of Rs. 286 crores, the stock hit a 5 percent upper circuit at Rs. 6.36 on BSE, despite a foreign portfolio investor (FPI) offloading a 1.16 percent stake in the company.
As per the latest bulk deal available with the BSE, Minerva Ventures Fund offloaded nearly 50 lakh equity shares in the company through an open market transaction. The deal was valued at approximately Rs. 3.24 crores, executed at an average price of Rs. 6.36 per share.
Leading Leasing Finance reported a significant growth in revenue from operations with an increase of nearly 780 percent YoY from Rs. 1.05 crores in Q3 FY24 to Rs. 9.24 crores in Q3 FY25. However, its net profit declined from Rs. 0.45 crores to a loss of Rs. 0.7 crores.
The company is mainly engaged in the business of lending, and has a diversified lending portfolio across retail, SME and commercial customers with a significant presence in urban and rural India. Leading Leasing Finance also accepts public and corporate deposits and offers a variety of financial services products to its customers.
Onyx Biotec Limited
With a market cap of Rs. 105.3 crores, the shares of this pharmaceutical company surged 8.2 percent to hit an intraday high at Rs. 58.95 on NSE, despite a foreign portfolio investor (FPI) selling a 1.46 percent stake in the company.
As per the latest bulk deal available with the NSE, Acintyo Investment Fund PCC divested 2.64 lakh equity shares in Onyx Biotec Limited through an open market transaction. The deal was valued at approximately Rs. 1.4 crores, executed at an average price of Rs. 53.19 per share.
The company reported a significant growth in revenue from operations with an increase of nearly 26 percent YoY from Rs. 24 crores in H2 FY24 to Rs. 30.2 crores in Q3 FY25. Similarly, its net profit grew by about 87.5 percent YoY from Rs. 1.6 crores to Rs. 3 crores.
Onyx Biotec Limited is one of the leading pharmaceutical companies engaged in the business of manufacturing, sale and distribution of generic and branded pharmaceutical products in various forms like water for injection (WFI), dry powder injections, and dry powder syrup.
Written by Shivani Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
